Abstracts Archive - Page 1163 of 2425 - ACR Meeting Abstracts

Abstract Number: 2378 • 2018 ACR/ARHP Annual Meeting
Subcutaneous Abatacept in Patients Aged 2–17 Years with Juvenile Idiopathic Arthritis and Inadequate Response to Biologic or Non-Biologic Disease-Modifying Antirheumatic Drugs: Results over 24 Months By Juvenile Idiopathic Arthritis Disease Category
Nicola Ruperto¹, Hermine I. Brunner², Gabriel Vega-Cornejo³, Alberto Berman⁴, Rubén J. Cuttica⁵, Francisco Ávila-Zapata⁶, Michael Henrickson⁷, Daniel J Kingsbury⁸, John F. Bohnsack⁹, Thomas Lutz¹⁰, Nadina E Rubio-Pérez¹¹, Valeria Gerloni¹², Xiaohui Li¹³, Marleen Nys¹⁴, Robert Wong¹³, Alberto Martini¹⁵ and Daniel J Lovell¹⁶, ¹Istituto Giannina Gaslini - Clinica Pediatrica e Reumatologia, Genoa, Italy, ²Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Clinica de Reumatología y Enfermedades Autoinmunes (CREA), Hospital México Americano, Guadalajara Jalisco, Mexico, ⁴Centro Médico Privado de Reumatología, Tucumán, Argentina, ⁵Hospital General de Niños Pedro de Elizalde, Buenos Aires, Argentina, ⁶Star Medica Hospital, Merida, Yucatán, Mexico, ⁷Cincinnati Children’s Medical Center, Cincinnati, OH, ⁸Randall Children’s Hospital at Legacy Emanuel, Portland, OR, ⁹University of Utah School of Medicine, Salt Lake City, UT, ¹⁰Pediatric Rheumatology, University Hospital, Center for Pediatric and Adolescent Medicine / Clinic 1, Heidelberg, Germany, ¹¹Universidad Autónoma de Nuevo León, Monterrey Nuevo León, Mexico, ¹²Istituto Gaetano Pini, Milan, Italy, ¹³Bristol-Myers Squibb, Princeton, NJ, ¹⁴Bristol-Myers Squibb, Braine L’Alleud, Belgium, ¹⁵Istituto G. Gaslini Pediatria II Reumatologia and University of Genova, Genova, Italy, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The effect of biologic DMARDs on different juvenile idiopathic arthritis (JIA) categories is poorly understood. In patients (pts) with JIA aged 2–17 years (y),…
Abstract Number: 2379 • 2018 ACR/ARHP Annual Meeting
Long-Term Safety of Subcutaneous Tocilizumab Administration in Systemic and Polyarticular Juvenile Idiopathic Arthritis
Hermine I. Brunner¹, Nicola Ruperto², Alberto Martini², Athimalaipet V. Ramanan³, Rubén J. Cuttica⁴, Jennifer E. Weiss⁵, Michael Henrickson¹, Heinrike Schmeling⁶, Jordi Anton⁷, Kirsten Minden⁸, Gerd Horneff⁹, María Luz Gámir-Gámir¹⁰, Markus Hufnagel¹¹, Wendy Douglass¹², Chris Wells¹², Sunethra Wimalasundera¹², Navita L. Mallalieu¹³, Daniel J Lovell¹ and Fabrizio De Benedetti¹⁴, ¹Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Pediatric Rheumatology International Trial Organization (PRINTO) Coordinating Centre, Genoa, Italy, ³Bristol Royal Hospital for Children, Bristol, United Kingdom, ⁴Hospital Gral de Niños Pedro Elizalde, Buenos Aires, Argentina, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Alberta Children’s Hospital/University of Calgary, Calgary, AB, Canada, ⁷Hospital Sant Joan de Deu, Barcelona, Spain, ⁸Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁹Asklepios Clinic Sankt Augustin, and University Hospital of Cologne, Cologne, Germany, ¹⁰Hospital Ramon y Cajal Unidad de Reumatologia Pediatrica, Madrid, Spain, ¹¹Department of Pediatrics and Adolescent Medicine, University Medical Center, Medical Faculty, University of Freiburg, Freiburg, Germany, ¹²Roche Products Ltd., Welwyn Garden City, United Kingdom, ¹³Roche Innovation Center, New York, NY, ¹⁴IRCCS Ospedale Pediatrico Bambino Gesù, Roma, Italy
Background/Purpose: Tocilizumab (TCZ) administered intravenously (IV) was shown to improve the signs and symptoms of polyarticular (p)JIA and systemic (s)JIA.1,2 An ongoing 3-year, long-term extension…
Abstract Number: 2380 • 2018 ACR/ARHP Annual Meeting
The Safety Profile of Adalimumab across Geographic Regions and Dosing Administrations Among Patients with Juvenile Idiopathic Arthritis Enrolled in a Registry
Hermine I. Brunner¹, Nicola Ruperto², Kabita Nanda³, Mary Toth⁴, Ivan Foeldvari⁵, John F. Bohnsack⁶, Diana Milojevic⁷, Daniel J Kingsbury⁸, Katherine A. Marzan⁹, Elizabeth Chalom¹⁰, Gerd Horneff¹¹, Rolf M. Kuester¹², Jason A Dare¹³, Maria Trachana¹⁴, Mareike Bereswill¹⁵, Hartmut Kupper¹⁵, Daniel J Lovell¹⁶ and Alberto Martini², ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Gaslini Institute and Pediatric Rheumatology International Trials Organisation, Genoa, Italy, ³Seattle Children's Hospital, Seattle, WA, ⁴Nemours Children’s Hospital, Orlando, FL, ⁵Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany, ⁶University of Utah, Salt Lake City, UT, ⁷Johns Hopkins All Children’s Hospital, St. Petersburg, FL, ⁸Randall Children’s Hospital, Portland, OR, ⁹Children's Hospital Los Angeles, Los Angeles, CA, ¹⁰The Pediatric Specialty Center at Saint Barnabas, West Orange, NJ, ¹¹Asklepios Children's Clinic, Sankt Augustin, Germany, ¹²Orthopädiezentrum Altona, Hamburg, Germany, ¹³Arkansas Children’s Hospital, Little Rock, AR, ¹⁴Hippokration General Hospital, Aristotle University, Thessaloniki, Greece, ¹⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁶PRCSG, Cincinnati Children’s Hospital Medical Center, Cinncinnati, OH
Background/Purpose: Adalimumab (ADA) has been approved for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) with long-term use often required to maintain disease control. The…
Abstract Number: 2381 • 2018 ACR/ARHP Annual Meeting
Long-Term Disease Control Among Patients with Juvenile Idiopathic Arthritis Receiving Adalimumab (Humira) Treatment for up to Six Years
Daniel J Lovell¹, Nicola Ruperto², Andreas Reiff³, Lawrence Jung⁴, Katerina Jarosova⁵, Richard Mouy⁶, Isabelle Koné-Paut⁷, Olcay Y. Jones⁸, Veronika Vargova⁹, Carine Wouters¹⁰, Ivan Lagunes Galindo¹¹, Carmen Mak¹², Hermine I. Brunner¹³ and Alberto Martini², ¹Cincinnati Children’s Medical Center and Pediatric Rheumatology Collaborative Study Group Coordinating Center, Cincinnati, OH, ²Gaslini Institute and Pediatric Rheumatology International Trials Organisation, Genoa, Italy, ³Children's Hospital Los Angeles, Los Angeles, CA, ⁴Children’s National Health Systems, Washington, DC, ⁵Institute of Rheumatology, Prague, Czech Republic, ⁶Hôpital Necker-Enfants Malades, Paris, France, ⁷Bicetre Hospital, APHP, University of Paris Sud, Paris, France, ⁸Walter Reed National Military Medical Center, Bethesda, MD, ⁹Faculty Hospital, Kosice, Slovakia, ¹⁰University Hospital Gasthuisberg, Leuven, Belgium, ¹¹AbbVie Inc., North Chicago, IL, ¹²AbbVie, North Chicago, IL, ¹³Pediatric Rheumatology Collaborative Study Group (PRCSG), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
Background/Purpose: Juvenile idiopathic arthritis (JIA) is a broad term that describes a clinically heterogeneous group of arthritides of unknown cause, which begin before 16 years…
Abstract Number: 2382 • 2018 ACR/ARHP Annual Meeting
Real-World Safety and Effectiveness of Adalimumab in Patients with Juvenile Idiopathic Arthritis: Results from a Post-Marketing Surveillance in Japan
Syuji Takei¹, Naomi Iwata², Ichiro Kobayashi^3,4, Toru Igarashi⁵, Yoko Yoshinaga⁶, Naoko Matsubara⁷, Naomi Sunaga⁸, Ayumi Ito⁷ and Shumpei Yokota⁹, ¹Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, ²Department of Immunology and Infectious Diseases, Aichi Children’s Health and Medical Center, Obu, Japan, ³Department of Allergy and Rheumatology, Chiba Children’s Hospital, Sapporo, Japan, ⁴Hokkaido University, Sapporo, Japan, ⁵Nippon Medical School, Tokyo, Japan, ⁶Evidence solution, Medical Communications, Medical, AbbVie GK, Tokyo, Japan, ⁷Medical, AbbVie GK, Tokyo, Japan, ⁸AbbVie GK, Tokyo, Japan, ⁹Fuji Toranomon Orthopedic Hospital, Gotemba, Japan
Background/Purpose: The safety and efficacy of adalimumab (an anti-TNF-α antibody) treatment in patients with JIA have been demonstrated in clinical trials. This study was conducted…
Abstract Number: 2383 • 2018 ACR/ARHP Annual Meeting
Pharmacovigilance of Biologics for Non-Systemic Juvenile Idiopathic Arthritis By the German Biologics Registry
Gerd Horneff¹, Gerd Ganser², Ivan Foeldvari³, Frank Weller-Heinemann⁴, Kirsten Minden⁵ and Ariane Klein⁶, ¹Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ²Klinik für Kinder-und Jugendrheumatologie, Nordwestdeutsches Rheumazentrum, Sendenhorst, Germany, ³Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ⁴Prof.-Hess-Kinderklinik, Bremen,, Berlin, Germany, ⁵Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁶Center of Pediatrics and Neonatology, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Long-term surveillance of biologics is particularly important in pediatric patients (pts) who may require prolonged treatment. Since 2001, the German Biologics JIA Registry (BIKER)…
Abstract Number: 2384 • 2018 ACR/ARHP Annual Meeting
Biosimilar Use in Young Adults with Juvenile Idiopathic Arthritis in Germany
Jens Klotsche¹, Martina Niewerth¹, Gerd Horneff² and Kirsten Minden^3,4, ¹Program Area Epidemiology, German Rheumatism Research Center, Berlin, Germany, ²Department of Pediatrics, Asklepios Clinics St. Augustin, Sankt Augustin, Germany, ³Charité–Universitätsmedizin Berlin, Berlin, Germany, ⁴German Rheumatism Research Center, Berlin, Germany
Background/Purpose: The first biosimilars have been approved for the treatment of juvenile idiopathic arthritis (JIA) in the last two years. To date, only a few…
Abstract Number: 2385 • 2018 ACR/ARHP Annual Meeting
The Childhood Arthritis and Rheumatology Research Alliance Start Time Optimization of Biologic Therapy in Polyarticular JIA Study: Updated Report of Baseline Patient Characteristics and Treatment Choices
Sarah Ringold¹, George A. Tomlinson², Pamela F. Weiss³, Laura E. Schanberg⁴, Mary Ellen Riordan⁵, Anne C. Dennos⁶, Vincent Del Gaizo⁷, Katherine Murphy⁸, Brian M. Feldman⁹ and Yukiko Kimura⁵, ¹Pediatric Rheumatology, Seattle Children's Hospital, Seattle, WA, ²Institute for Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada, ³Division of Rheumatology, Center for Pediatric Clinical Effectiveness, Children's Hospital of Philadelphia, Philadelphia, PA, ⁴Duke University Medical Center, Durham, NC, ⁵Hackensack University Medical Center, Hackensack, NJ, ⁶Duke Clinical Research Institute, Durham, NC, ⁷Parent Partner, Whitehouse Station, NJ, ⁸Parent Partner, San Francisco, CA, ⁹Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada
Background/Purpose: There is significant variation in the timing of when biologic medications are started during initial treatment for polyarticular juvenile idiopathic arthritis (P-JIA) in clinical…
Abstract Number: 2386 • 2018 ACR/ARHP Annual Meeting
Secukinumab Is a Promising Treatment for Patients with Juvenile Enthesitis Related Arthritis Nonresponsive to Anti-TNF Treatment
Ivan Foeldvari and Jean Baer, Hamburg Center for Pediatric and Adolescent Rheumatology, Hamburg, Germany
Background/Purpose: Secukinumab (SEC) is licensed to treat adults with spondyloarthritis. It is not licensed for pediatric patients with Juvenile Idiopathic Enthesitis related Arthritis (enthJIA) yet.…
Abstract Number: 2387 • 2018 ACR/ARHP Annual Meeting
Resurrecting Triamcinolone Hexacetonide (the Steroid Formerly Known as Aristospan®): Efficacy and Safety of a Compounded Preparation of Triamcinolone Hexacetonide for Intra-Articular Injection in Children with Arthritis
C. April Bingham¹, Lisabeth Scalzi¹, Diane Boomsma², Brandt Groh¹, Natalya Gaffney¹, Sarah Sertial¹, Timothy Hahn¹, Vincent Lacroce³ and Barbara Ostrov¹, ¹Pediatrics, Penn State Children's Hospital, Hershey, PA, ²Pharmacy, Custom Prescriptions of Lancaster, Lancaster, PA, ³Pharmacy, Penn State Milton S. Hershey Medical Center, Hershey, PA
Background/Purpose: Intra-articular triamcinolone hexacetonide (TH) historically provided longer-lasting control of chronic arthritis in children than comparator intra-articular glucocorticoid preparations such as triamcinolone acetonide (TA) (J…
Abstract Number: 2388 • 2018 ACR/ARHP Annual Meeting
Assessment of Treatment Responses, with Special Reference to Remission Using Juvenile Arthritis Disease Activity Score (JADAS), in the Different Categories of Juvenile Idiopathic Arthritis
Debanjali Sinha¹, Sumantro Mondal¹ and Alakendu Ghosh², ¹Rheumatology, Senior Resident (Academic), Kolkata, India, ²Rheumatology, Professor and Head of Department, Kolkata, India
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) isthe most common chronic rheumatologic disease in children, which can significantly compromise quality of life. The objective of the study…
Abstract Number: 2389 • 2018 ACR/ARHP Annual Meeting
Evaluating Disease Activity Outcomes for Juvenile Idiopathic Arthritis across the Pediatric Rheumatology Care and Outcomes Improvement Network (PR-COIN)
Emily A. Smitherman¹, Bin Huang², Ronald M. Laxer³, C. April Bingham⁴, Cagri Yildirim-Toruner⁵, Beth Gottlieb⁶, Jennifer Weiss⁷, Tzielan Lee⁸, Sheetal S. Vora⁹, Jon (Sandy) Burnham¹⁰, Julia Harris¹¹, Judyann C. Olson¹², Mileka Gilbert¹³, Michelle Batthish¹⁴, Michael Shishov¹⁵, Dustin Fleck¹⁶ and Esi Morgan¹, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Div of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁴Penn State Health Children's Hospital, Hershey, PA, ⁵Division of Rheumatology, Nationwide Children’s Hospital, Columbus, OH, ⁶Pediatric Rheumatology PTD, Cohen Children's Medical Center of New York, Lake Success, NY, ⁷Hackensack University Medical Center, Hackensack, NJ, ⁸Pediatric Rheumatology, Stanford University, Palo Alto, CA, ⁹Pediatric Rheumatology, Levine Children's Hospital, Charlotte, NC, ¹⁰Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ¹¹Children's Mercy - Kansas City, Kansas City, MO, ¹²Ped/MACC Fund Research Ctr, Medical College of Wisconsin, Milwaukee, WI, ¹³Pediatric Rheumatology, Medical University of South Carolina, Charleston, SC, ¹⁴Division of Pediatric Rheumatology, McMaster Children's Hospital, Hamilton, ON, Canada, ¹⁵Phoenix Children's Hospital, Phoenix, AZ, ¹⁶Pediatric Rheumatology, University of Michigan, Brighton, MI
Background/Purpose: It is widely accepted that the treatment goal for juvenile idiopathic arthritis (JIA) is remission. PR-COIN, a quality improvement collaborative comprised of pediatric rheumatology…
Abstract Number: 2390 • 2018 ACR/ARHP Annual Meeting
Incidence of and Risk Factors for Adrenal Suppression Following Ultrasound-Guided Intra-Articular Corticosteroid Injection with Triamcinolone Acetonide in Juvenile Idiopathic Arthritis
Katherine K Ngo¹, Angelina Bernier¹, Melissa E Elder², Renee F Modica² and Akaluck Thatayatikom¹, ¹Pediatrics, University of Florida, Gainesville, FL, ²Department of Pediatrics, University of Florida, Gainesville, FL
Background/Purpose: Intra-articular corticosteroid injection (IACI) is routinely used in juvenile idiopathic arthritis (JIA) with oligoarticular disease and as adjunct therapy for other types of JIA.…
Abstract Number: 2391 • 2018 ACR/ARHP Annual Meeting
Methotrexate Polyglutamates As an Evaluation Tool for Appropriate Dosage of Oral Methotrexate Administration in Pediatric Patients
Nami Okamoto¹, Kosuke Shabana², Yasuo Nakagishi³, Kenichi Nishimura⁴, Mao Mizuta⁵, Yuka Okura⁶, Masaki Shimizu⁵, Hiroyuki Wakiguchi⁷, Junko Yasumura⁸ and Masaaki Mori⁹, ¹Pediatrics, Osaka Medical College, Takatsuki, Japan, ²Department of Pediatrics, Osaka Medical College, Takatsuki, Japan, ³Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, Kobe, Japan, ⁴Department of Pediatrics, Yokohama City University Graduate School of Medicine, Yokohama, Japan, ⁵Department of Pediatrics, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Japan, ⁶Department of Pediatrics, KKR Sapporo Medical Center, Sapporo, Japan, ⁷Department of Pediatrics, Yamaguchi University Graduate School of Medicine, Ube, Japan, ⁸Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan, ⁹Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Since MTX metabolism varies depending on age and dosage, we need to know optimal MTX administration method in children. We performed multi-center prospective study…
Abstract Number: 2392 • 2018 ACR/ARHP Annual Meeting
Are Single Nucleotide Polymorphisms in Methotrexate Transporter Proteins Associated with Methotrexate Intolerance in Juvenile Idiopathic Arthritis?
Nini Kyvsgaard¹, Torben Mikkelsen¹, Anne Estmann², Thomas Als³, Jane Hvarregaard Christensen³, Thomas Corydon³ and Troels Herlin¹, ¹Pediatric and Adolescent Medicine, Aarhus University Hospital, Aarhus N, Denmark, ²Department of Pediatric Rheumatology, H.C. Andersen's Children's Hospital, Odense, Denmark, ³Department of Biomedicine, Aarhus University, Aarhus C, Denmark
Background/Purpose: Methotrexate (MTX) intolerance is common in juvenile idiopathic arthritis (JIA) and poses the risk of premature termination of an effective treatment. MTX intolerance is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].